DE69927507D1 - Zusammensetzungen und verfahren zur behandlung von abnormaler zellvermehrung - Google Patents

Zusammensetzungen und verfahren zur behandlung von abnormaler zellvermehrung

Info

Publication number
DE69927507D1
DE69927507D1 DE69927507T DE69927507T DE69927507D1 DE 69927507 D1 DE69927507 D1 DE 69927507D1 DE 69927507 T DE69927507 T DE 69927507T DE 69927507 T DE69927507 T DE 69927507T DE 69927507 D1 DE69927507 D1 DE 69927507D1
Authority
DE
Germany
Prior art keywords
abnormal cell
vitamin
compositions
treatment
cell reproduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69927507T
Other languages
English (en)
Other versions
DE69927507T2 (de
Inventor
Pharma A S Ballerup Leo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Application granted granted Critical
Publication of DE69927507D1 publication Critical patent/DE69927507D1/de
Publication of DE69927507T2 publication Critical patent/DE69927507T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
    • A61Q5/065—Preparations for temporary colouring the hair, e.g. direct dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69927507T 1998-07-16 1999-07-13 Zusammensetzungen und verfahren zur behandlung von abnormaler zellvermehrung Expired - Fee Related DE69927507T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US116632 1998-07-16
US09/116,632 US20010002396A1 (en) 1998-07-16 1998-07-16 Compositions and methods of treating skin conditions
PCT/US1999/015769 WO2000003700A1 (en) 1998-07-16 1999-07-13 Compositions and methods of treating abnormal cell proliferation

Publications (2)

Publication Number Publication Date
DE69927507D1 true DE69927507D1 (de) 2006-02-09
DE69927507T2 DE69927507T2 (de) 2006-03-23

Family

ID=22368338

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69927507T Expired - Fee Related DE69927507T2 (de) 1998-07-16 1999-07-13 Zusammensetzungen und verfahren zur behandlung von abnormaler zellvermehrung

Country Status (12)

Country Link
US (2) US20010002396A1 (de)
EP (1) EP1104294B8 (de)
JP (1) JP2002527356A (de)
AT (1) ATE305296T1 (de)
AU (1) AU4988999A (de)
CA (1) CA2337138A1 (de)
DE (1) DE69927507T2 (de)
DK (1) DK1104294T3 (de)
ES (1) ES2249900T3 (de)
MX (1) MXPA01000492A (de)
PT (1) PT1104294E (de)
WO (1) WO2000003700A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6538037B2 (en) 1991-01-08 2003-03-25 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US6573256B2 (en) 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6503893B2 (en) 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
ATE515265T1 (de) * 1998-03-27 2011-07-15 Univ Oregon Health & Science Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
US8263580B2 (en) * 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
DE10010814A1 (de) * 2000-03-08 2001-09-13 Basf Ag Verwendung von 4-Oxoretinol und dessen Derivaten in kosmetischen Zubereitungen
EP2070911A2 (de) * 2000-07-18 2009-06-17 Bone Care International, Inc. Stabilisiertes 1-alpha-Hydroxy-Vitamin D
US6566399B2 (en) * 2000-08-03 2003-05-20 Byung-Moo Min Inhibitor of replicative senescence of human keratinocytes containing retinoic acid as active ingredients
IL162213A0 (en) * 2001-12-03 2005-11-20 Novacea Inc Pharmaceutical compositions containing active vitamin d compounds
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
US7273607B2 (en) * 2002-07-01 2007-09-25 Karl G. Schakel, legal representative Health enhancement method
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
KR20050096953A (ko) * 2003-02-05 2005-10-06 갈데르마 리써어치 앤드 디벨로프먼트,에스.엔.씨. 물의 존재에 민감한 하나 이상의 활성제를 함유하는 반전에멀젼 유형 조성물, 및 미용 및 피부과에서의 그의 용도
CN103265477B (zh) * 2003-02-26 2017-01-11 苏根公司 作为蛋白激酶抑制剂的氨基杂芳基化合物
EP1628631A2 (de) * 2003-06-05 2006-03-01 Achkar, Charles C. Verfahren zur behandlung von hyperproliferativen zellerkrankungen
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
FR2862540B1 (fr) * 2003-11-21 2007-03-30 Galderma Res & Dev Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
US8404667B2 (en) * 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
FR2871699A1 (fr) * 2004-06-17 2005-12-23 Galderma Sa Composition de type emulsion inverse contenant du calcitrol et du 17-propionate de clobetasol, et ses utilisations en cosmetiques et en dermatologie
US20060003950A1 (en) * 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
US20060177390A1 (en) * 2005-02-08 2006-08-10 Person John R Skin cancer prevention method and product
US20060073107A1 (en) * 2004-10-04 2006-04-06 Person John R Use of vitamin D3 (cholecalciferol) in sunscreens
US20100093674A1 (en) * 2005-08-04 2010-04-15 Person John R Skin cancer prevention method and product
CA2608021A1 (en) * 2005-05-10 2006-11-16 Dermipsor Ltd. Compositions and methods for skin care
BRPI0609630A2 (pt) * 2005-05-10 2010-04-20 Dermipsor Ltd composições e métodos para tratamento de doenças epidérmicas hiperproliferativas
WO2006133828A1 (en) * 2005-06-17 2006-12-21 Dsm Ip Assets B.V. Novel use 25-hydroxycholecalciferol in combination with uv-b screening agents
FR2894465B1 (fr) * 2005-12-14 2010-09-10 Fabre Pierre Dermo Cosmetique Utilisation de composes polyinsatures en tant qu'agents blanchissants
US20080275128A1 (en) 2007-04-27 2008-11-06 Elliott C Lasser Compositions and methods for the treatment of inflammatory conditions
CN105663146B (zh) 2009-08-14 2020-09-11 博格有限责任公司 用于治疗脱发的维生素d3及其类似物
US8747818B1 (en) 2011-02-07 2014-06-10 Dennis Gross Self-tanning compositions
EP3134093B1 (de) * 2014-04-23 2020-09-09 The Regents of the University of California Analoga von n-acetylglucosamin und verwendungen davon
CN106852126A (zh) * 2014-06-04 2017-06-13 阿尔邦国际有限公司 用于递送皮肤护理用活性成分的透明组合物和方法
EP3939593A1 (de) * 2014-09-10 2022-01-19 Washington University Zusammensetzungen und verfahren zur behandlung von präkanzerogenen hautläsionen
CN112805007B (zh) * 2018-03-07 2023-12-15 慧源香港创新有限公司 用于治疗过度增殖性皮肤障碍的组合物和方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514672A (en) 1981-02-17 1996-05-07 Bazzano; Gail S. Use of retinoids and compositions containing same for hair growth
WO1984002845A1 (en) * 1983-01-21 1984-08-02 Advanced Drug Tech Vitamin-containing skin care ointment
JPH07100685B2 (ja) * 1985-08-02 1995-11-01 レオ・ファ−マシュ−ティカル・プロダクツ・リミテッド・エイ／エス（レ−ベンス・ケミスケ・ファブリック・プロデュクチオンスアクチ−セルスカブ） 新規ビタミンｄ類似体
JPS6360910A (ja) 1986-09-01 1988-03-17 Shiseido Co Ltd 皮膚外用剤
US5763428A (en) * 1990-09-21 1998-06-09 Bone Care International, Inc. Methods of treating skin disorders with novel 1a-hydroxy vitamin D4 compounds and derivatives thereof
GB9109733D0 (en) * 1991-05-07 1991-06-26 Unilever Plc Cosmetic composition
TW272187B (de) 1992-05-20 1996-03-11 Hoffmann La Roche
US5547947A (en) * 1993-03-11 1996-08-20 Hoffmann-La Roche Inc. Methods of treatment
FR2714595B1 (fr) 1993-12-30 1996-02-02 Oreal Emulsion eau dans huile contenant du rétinol, son utilisation et son conditionnement.
DE69529043T2 (de) 1994-09-30 2003-05-08 Oreal Verwendung von einem Agonisten eines mit einem Chloridkanal assozierten Rezeptors zur Behandlung von Hautfalten
US5786391A (en) 1995-01-11 1998-07-28 Cornell Research Foundation, Inc. Regulating gene expression using retinoids with Ch2 OH or related groups at the side chain terminal position
FR2738745B1 (fr) 1995-09-15 1997-10-24 Cird Galderma Nouvelles compositions a base d'un melange synergetique entre au moins un ligand de vdr et un retinoide, et leurs utilisations

Also Published As

Publication number Publication date
US6242435B1 (en) 2001-06-05
US20010002396A1 (en) 2001-05-31
EP1104294A1 (de) 2001-06-06
DE69927507T2 (de) 2006-03-23
ES2249900T3 (es) 2006-04-01
DK1104294T3 (da) 2006-02-13
AU4988999A (en) 2000-02-07
WO2000003700A1 (en) 2000-01-27
EP1104294A4 (de) 2003-02-05
PT1104294E (pt) 2005-11-30
CA2337138A1 (en) 2000-01-27
ATE305296T1 (de) 2005-10-15
MXPA01000492A (es) 2002-11-29
JP2002527356A (ja) 2002-08-27
EP1104294B8 (de) 2005-11-23
EP1104294B1 (de) 2005-09-28

Similar Documents

Publication Publication Date Title
DE69927507D1 (de) Zusammensetzungen und verfahren zur behandlung von abnormaler zellvermehrung
DE59407237D1 (de) Nitrato-aminosäure-disulfide zur therapie von erkrankungen des herz-kreislauf-systems
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
PT76472A (de) Neue derivate von cycloalka<c>pyrrol-carbonsaeuren verfahren zu ihrer herstellung diese enthaltende mittel und deren verwendung sowie neue cycloalka<c>pyrrol-carbonsaeuren als zwischenstufen und verfahren zu deren herstellung
MY141384A (en) Prevention of loss and restoration of bone mass by certain prostaglandin agonists
UA49011C2 (uk) Похідні циклічної амінокислоти, фармацевтична композиція та спосіб лікування
IE840302L (en) 3-(5-aminopentyl)amino-1-benzazepin-2-one-1-alkanoic acids.
IL124954A (en) Inhibitors of interleukin-1betaconverting enzyme and pharmaceutical compositions containing the same
ATE406808T1 (de) Zusammensetzungen, die kurz-und langkettige fettsäuren enthalten, sowie verfahren zu ihrer anwendung für die kontrolle des körpergewichts
UA66745C2 (en) INTERLEUKIN-1b-CONVERTING ENZYME INHIBITORS, PHARMACEUTICAL COMPOSITION AND A METHOD FOR TREATMENT OF DISEASES
EP0911321A3 (de) Verbindungen zur Behandlung von Osteoporose
MY119231A (en) Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them
ATE207349T1 (de) Thip zur behandlung von schlafstörungen
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
DE69926400D1 (de) Zusammensetzung enthaltend insulin-sensibilisierenden wirkstoffe und inhibitoren der fruktose-1,6-bisphosphatase (fbpase) zur behandlung von diabetes
AP9801269A0 (en) Prostaglandin agonists.
AU8647101A (en) Compounds having activity as inhibitors of cytochrome p450rai
ATE266030T1 (de) 1,4,7,10-tetraazabicyclo(8.2.2)tetradecan-2-on, verfahren zu ihrer herstellung und ihrer verwendung für die herstellung von tetraazamacrocyclen
DE69516903D1 (de) Retinoid trienverbindungen und verfahren
ATE293595T1 (de) Thyroidhormon-analoga und verfahren zu ihrer herstellung
ATE464378T1 (de) Verwendung des globulären kopfes von acrp30 zur verstärkung der zunahme von muskelmasse und - differenzierung
BR0315247A (pt) Composição, composição farmacêutica, método de tratamento para uma doença proliferativa celular, e, kit
ATE181361T1 (de) Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie
BR0210493A (pt) Composição, e, método para remover cerume humano
DE69613395D1 (de) Schwefelenthaltende di-ter-butylphenol-verbindungen brauchbar als entzündungshemmende mittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee